190 related articles for article (PubMed ID: 30711772)
21. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Kanjanapan Y; Day D; Butler MO; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S; Chappell M; Chow K; Sherwin B; Stayner LA; Soultani L; Zambrana A; Siu LL; Bedard PL; Spreafico A
Eur J Cancer; 2019 Jan; 107():1-7. PubMed ID: 30529898
[TBL] [Abstract][Full Text] [Related]
22. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
23. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
24. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Sessa C; Lorusso P; Tolcher A; Farace F; Lassau N; Delmonte A; Braghetti A; Bahleda R; Cohen P; Hospitel M; Veyrat-Follet C; Soria JC
Clin Cancer Res; 2013 Sep; 19(17):4832-42. PubMed ID: 23833302
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.
Lee SJ; Lee SY; Lee WS; Yoo JS; Sun JM; Lee J; Park SH; Park JO; Ahn MJ; Lim HY; Kang WK; Park YS
Invest New Drugs; 2017 Dec; 35(6):782-790. PubMed ID: 28391576
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
27. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
28. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
29. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
30. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
33. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
34. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
36. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK; Humphrey R; Hammond LA; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen JM; Von Hoff DD; Eckhardt SG
J Clin Oncol; 2000 Jan; 18(1):178-86. PubMed ID: 10623708
[TBL] [Abstract][Full Text] [Related]
38. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD; Von Hoff DD; Adjei AA; Leffingwell DP; Eckhardt SG; Gore L; Lewis KD; Weiss GJ; Ramanathan RK; Dy GK; Ma WW; Sheedy B; Iverson C; Miner JN; Shen Z; Yeh LT; Dubowy RL; Jeffers M; Rajagopalan P; Clendeninn NJ
Clin Cancer Res; 2013 Mar; 19(5):1232-43. PubMed ID: 23434733
[TBL] [Abstract][Full Text] [Related]
39. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
40. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
